REGULATORY

• Japan Health Ministry Panel Gives Blessing to Novartis’ PNH Drug Iptacopan and More
  June 4, 2024

• Make Single IRB Mandatory in Multi-Center Trials That Use Competitive Funds: Deregulation Panel
  June 4, 2024

• Finance Minister Acknowledges Wholesalers’ Plight with Frequent Drug Price Revisions
  May 31, 2024

• Nitrosamine Guideline to Be Proposed as New Topic for ICH at Fukuoka Confab
  May 31, 2024

• Expand Mixed-Billing Scheme to Cover Gene Panel Test: LDP Committee Proposal
  May 31, 2024

• Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
  May 30, 2024

• PMDA Cuts Fees for Pediatric, Orphan Drug Consultations
  May 30, 2024

• LDP Lawmakers’ League on Generics Prods Minister to Rethink Off-Year Revisions
  May 29, 2024

• Health Minister Acknowledges Changes after 2016 Decision on Off-Year Revisions
  May 28, 2024

• MHLW Panel OKs Avigan for SFTS with Strings Attached, Shionogi COVID Jab Only for Primary Use
  May 27, 2024

• LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
  May 24, 2024

• MHLW Proposes Inclusion of Prevenar 20 in National Immunization for Children
  May 24, 2024

• MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report
  May 23, 2024

• Japan Govt to Launch Public-Private Forum to Attract Investments
  May 23, 2024

• No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
  May 23, 2024

• Japan to Survey Uneven Distribution of Yakkasa, Look into Voluntary Chain Deals Too
  May 23, 2024

• Fresh Panel Discussion for Avigan’s SFTS Use Set for May 24
  May 23, 2024

• LDP Project Team Finalizes Proposal, Pushes Rethink of Off-Year Revisions
  May 22, 2024

• MOF Panel Urges Full-Scale Off-Year Revisions, Enhanced CEA: “Spring” Proposal
  May 22, 2024

• Off-Year Price Revisions Should Either Be Abolished or Revisited: LDP Lawmakers
  May 21, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• …
• Next ›
• 最終 »